Washington, DC 20549
|
FORM
|
CURRENT REPORT
|
Date of Report (Date of earliest event reported):
|
|
(Exact name of Registrant as specified in its charter)
|
|
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
Item 8.01 |
Other Events.
|
Dated: April 13, 2023
|
||
Aquestive Therapeutics, Inc.
|
||
By:
|
/s/ A. Ernest Toth, Jr
|
|
Name: A. Ernest Toth, Jr.
|
||
Title: Chief Financial Officer
|
Document and Entity Information |
Apr. 13, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Apr. 13, 2023 |
Entity File Number | 001-38599 |
Entity Registrant Name | Aquestive Therapeutics, Inc. |
Entity Central Index Key | 0001398733 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 82-3827296 |
Entity Address, Address Line One | 30 Technology Drive |
Entity Address, City or Town | Warren |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07059 |
City Area Code | 908 |
Local Phone Number | 941-1900 |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | AQST |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
P1G_](-_X_U*\'4JO@ZE7@=PL$SXNHF"[K_BB0:"X[KBN#XO-00MJ$BABF96-<:*4JC=KR MZ*9"NR$%#[G]*!)@ST6Z!-4$16MXGG_9Z5\/!@1/K^+IGIU!O]>A9G-080W.P<)!2I5+57K5!9L;S#4F%9O* GD16T:-(:7%[Q\( M0M^KG=4[AW'!M^PIPOB)E0A+4"+_6B3[ >9?T L&-Q3AD??[YQ!.H@A]$7/F M<,'>XW/L8]88NA;)CL<6$,:93.1ZQ^X5)B:%6E^: 'T*I*X+/FWJ[V6(,9G%,J,* M0XO(H.M?^@//HXCJRN#3EKX0!HN47#$_^'GY"YM#6"B,5B,6K325:8I^,S =E8ZY(I=H72E\VN 7BD )_/[R2=J%UM7@^"L:O"0@EK;*/V& M"B;&Y$]SGC7.;8N@404U;T%=!8*SJL##EN$,XG&K+%'[#5PC%JW6MI4,CC;^ M+1Z-4V@@LR%*B^Q0.W4C$BW4BE1[?4#[\EPF(L0 X?Q]0)=7@C?F>8M**T]M M\ %MQS,%ER&&![#,[ \A> [ 1?UQM6JVL1:]5K+:W@/:G;\C>]*Z0+)60%KV M)*![= 2V?R=\X':9:9; "H6\JQ[JJOT)?=\P,B]/Q4MI\(Q=7L; D &PO M 9KEMWDOSAR+DCO9*ZW="C<\W[)&D/ M1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O M:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\" MO @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9 MY=VI\0QKRTZ+Y2T].PP_/LG>V)+;. '36-/+T08I:*Q[V_LL) MBS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W M3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y M]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5T MR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00, MX[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/ M+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^ M>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( %N+C5:7BKL -8?20$3;8T.P6BP^0"X99K>]9!:G
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end
BWHO1,\.DMFU
MLED?.[BS]\\?L&?NO%YDGX&K@9[G^.SB"UH9;=0!